Company Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
959.9 USD -0.47% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.47% +9.29%

Business Summary

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:

- revenues from product sales (56.6%);

- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);

- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.

At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.

Number of employees: 13,450

Sales per Business

USD in Million2022Weight2023Weight Delta
Medicines
100.0 %
12,173 100.0 % 13,117 100.0 % +7.76%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
51.5 %
6,821 56.0 % 6,754 51.5 % -0.98%
Rest of World
44.4 %
4,987 41.0 % 5,827 44.4 % +16.85%
Other
4.1 %
365 3.0 % 536 4.1 % +46.84%

Managers

Managers TitleAgeSince
Founder 64 88-01-07
Chief Executive Officer 71 88-01-07
Director of Finance/CFO 54 02-12-31
Compliance Officer - 21-12-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 66 98-12-31
Chief Tech/Sci/R&D Officer 67 90-12-31
Chief Operating Officer - 97-12-31
Chief Tech/Sci/R&D Officer - 18-12-31
Public Communications Contact - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 71 10-11-11
Chief Executive Officer 71 88-01-07
Director/Board Member 82 91-05-31
Director/Board Member 83 91-05-31
Director/Board Member 74 88-01-07
Founder 64 88-01-07
Director/Board Member 81 02-12-31
Director/Board Member 63 17-02-16
Director/Board Member 66 23-09-07
Director/Board Member 61 16-09-11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 10 1,818,146 0 0 77.18 %
Stock B 1 133,443,750 104,398,850 ( 78.23 %) 25,500,000 ( 19.11 %)

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
9.556 %
10,314,898 9.556 % 9 965 M $
Vanguard Fiduciary Trust Co.
8.188 %
8,838,285 8.188 % 8 539 M $
JPMorgan Investment Management, Inc.
6.688 %
7,218,986 6.688 % 6 974 M $
BlackRock Advisors LLC
6.179 %
6,669,633 6.179 % 6 443 M $
Capital Research & Management Co. (World Investors)
4.753 %
5,130,485 4.753 % 4 957 M $
4,901,251 4.541 % 4 735 M $
Capital Research & Management Co. (International Investors)
2.701 %
2,915,972 2.701 % 2 817 M $
Dodge & Cox
2.193 %
2,367,680 2.193 % 2 287 M $
Geode Capital Management LLC
2.181 %
2,354,217 2.181 % 2 274 M $
BlackRock Life Ltd.
1.651 %
1,782,557 1.651 % 1 722 M $
NameEquities%Valuation
1,726,565 82.61 % 1 668 M $
42,750 2.045 % 41 M $
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000397 %
25,644 0.000397 % 416 402 $
Bram Bradesco Asset Management S/A DTVM
0.000264 %
17,048 0.000264 % 276 822 $

Company contact information

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

10591-6707, Tarrytown

+914 847 7000

http://www.regeneron.com
address Regeneron Pharmaceuticals, Inc.(REGN)

Group companies

NameCategory and Sector
Biotechnology